Advertisement

PROPRANOLOL AND INFANTILE HEMANGIOMAS: OUTCOME FROM A TRICENTRIC STUDY

Published:November 22, 2022DOI:https://doi.org/10.1016/j.bjps.2022.11.016

      Abstract

      Introduction

      The introduction of propranolol as systemic therapy for infantile hemangiomas (IH) has changed the natural history of these tumors. Cases presenting with ulceration, functional limitation, and visceral or life-threatening localization are excellent indications to medical therapy. The aim was to report the medium term follow-up after the introduction of propranolol in 3 referral centers with particular attention to outcome and surgical treatments.

      Materials and Methods

      In the period 2011-2018 348 patients underwent systemic therapy with propanolol at a mean age of 3.5 months (range 1-10). The indications to begin the treatment were: visceral localization (10,6%), ulceration (20%), risk of severe aesthetic impairment (27%), and peri-orifices localization (42.4%).

      Results

      The minimum follow-up was 1 year. Propranolol was administered for a mean of 11 months (range: 6-19) and in 22 cases it was resumed for extra 4.5 months due to rebound. Overall, 97.4% responded to therapy without severe side effects. Seven patients underwent surgery and 9 laser therapy . Twenty-four cases are scheduled for surgery for evident inesthetisms and 4 will undergo laser therapy to complete the treatment.

      Conclusions

      The use of propranolol has considerably decreased the surgical indications for IH, improved the aesthetic and functional outcome, and simplified the definitive surgical treatment. The response rate to therapy is very high and in case of failure both laser and surgery are still very effective. The correct diagnosis, early starting, and adequate duration of therapy are key factors for the success of treatment.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Plastic, Reconstructive & Aesthetic Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Darrow D H
        • Greene AK
        • Mancini AJ
        • Nopper AJ.
        Diagnosis and Management of Infantile Hemangioma.
        PEDIATRICS October. 2015; 136 (number 4)
        • Krowchuk D P
        • Frieden I J
        • Mancini AJ
        • et al.
        Clinical Practice Guideline for the Management of Infantile Hemangiomas.
        Pediatrics. 2019; 143: 1-28
        • Léauté-Labrèze C
        • Hoeger P
        • Mazereeuw-Hautier J
        • et al.
        Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma.
        N Engl J Med. 2015; 372: 735-746
        • Léaute-Labrèze C
        • Boccara O
        • Degrugillier-Chopinet C
        • et al.
        Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review.
        PEDIATRICS. October 2016; 1 (number 4): 38
        • Yuzuriha S
        • Nagai F
        • Noguchi M.
        How to Manage Disfiguring Scars in Involuted Infantile hemangioma.
        Adv Wound Care (New Rochelle). 2019; 8: 221-229